Manufacturers: LongBio Pharma
LP-003 is a novel anti-IgE antibody developed by LongBio Pharma for the treatment of chronic spontaneous urticaria (CSU). In top-line results, it demonstrated significantly better efficacy than omalizumab, positioning it as a next-generation anti-IgE therapeutic.
LP-003 is a novel anti-IgE antibody developed by LongBio Pharma for the treatment of chronic spontaneous urticaria (CSU). In top-line results, it demonstrated significantly better efficacy than omalizumab, positioning it as a next-generation anti-IgE therapeutic.
LP-003 is a novel anti-IgE antibody that blocks free IgE in the blood and tissues, thereby inhibiting IgE-mediated allergic reactions.
Chronic spontaneous urticaria (CSU) — in top-line results, LP-003 exhibited significantly better efficacy than omalizumab.
1 associated conditions
